Replies to post #240226 on Biotech Values

[Hanibal]

Daytraders got ahold of this one due to its low float

[DewDiligence]

MYNZ +40% on upgrade to ColoAlert diagnostic for colorectal cancer:

https://www.globenewswire.com/news-release/2022/01/05/2361340/0/en/Mainz-Biomed-Acquires-Exclusive-Rights-to-Novel-mRNA-Biomarkers.html

ColoAlert is approved in the EU but not (yet) in the US. It is similar in design to EXAS’ Cologuard.

MYNX has almost tripled from its Nasdaq IPO in November.